Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database

다국어 초록 (Multilingual Abstract)

Background: We assessed the association of dipeptidyl peptidase 4 inhibitors (DPP4i) with hospitalization for heart failure (HF) using the Korean Health Insurance claims database.
Methods: We collected data on newly prescribed sitagliptin, vildagliptin, and pioglitazone between January 1, 2009 and December 31, 2012 (mean follow-up of 336.8 days) to 935,519 patients with diabetes (518,614 males and 416,905 females) aged 40 to 79 years (mean age of 59.4 years).
Results: During the study, 998 patients were hospitalized for primary HF (115.7 per 100,000 patient-years). The incidence rate of hospitalization for HF was 117.7 per 100,000 per patient-years among patients on pioglitazone, 105.7 for sitagliptin, and 135.8 for vildagliptin. The hospitalization rate for HF was greatest in the first 30 days after starting the medication, which corresponded to a significantly higher incidence at days 0 to 30 compared with days 31 to 360 for all three drugs. The hazard ratios were 1.85 (pioglitazone), 2.00 (sitagliptin), and 1.79 (vildagliptin). The incidence of hospitalization for HF did not differ between the drugs for any time period.
Conclusion: This study showed an increase in hospitalization for HF in the initial 30 days of the DPP4i and pioglitazone compared with the subsequent follow-up period. However, the differences between the drugs were not significant.

참고문헌 (Reference)

1 Hernandez AV, "Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and metaregression analysis of placebo-controlled randomized clinical trials" 11 : 115-128, 2011

2 Park C, "The incidence and residual lifetime risk of osteoporosis-related fractures in Korea" 29 : 744-751, 2011

3 Hiatt WR, "The cardiovascular safety of diabetes drugs: insights from the rosiglitazone experience" 369 : 1285-1287, 2013

4 McMurray J, "The Vildagliptin in Ventricular Dysfunction Diabetes (VIVIDD) trial" European Society of Cardiology 99-, 2013

5 Weir DL, "Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study" 2 : 573-582, 2014

6 Scirica BM, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus" 369 : 1317-1326, 2013

7 Nissen SE, "Rosiglitazone revisited: an updated metaanalysis of risk for myocardial infarction and cardiovascular mortality" 170 : 1191-1201, 2010

8 Marney A, "Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans" 56 : 728-733, 2010

9 Skyler JS, "Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association" 32 : 187-192, 2009

10 Nathan DM, "Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes" 353 : 2643-2653, 2005

11 Laakso M, "Insulin resistance and hyperglycaemia in cardiovascular disease development" 10 : 293-302, 2014

12 Krum H, "Heart failure and dipeptidyl peptidase-4 inhibitors" 16 : 603-607, 2014

13 Ban K, "Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39)yet does not require the known GLP-1 receptor" 151 : 1520-1531, 2010

14 Gustavson SM, "Effects of a long-acting GLP-1mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus" 13 : 1056-1058, 2011

15 Sachdeva A, "Discontinuation of long-term clopidogrel therapy is associated with death and myocardial infarction after saphenous vein graft percutaneous coronary intervention" 60 : 2357-2363, 2012

16 Monami M, "Dipeptidyl peptidase-4inhibitors and heart failure: a meta-analysis of randomized clinical trials" 24 : 689-697, 2014

17 Monami M, "Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials" 15 : 112-120, 2013

18 Wu S, "Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants" 32 : 147-158, 2014

19 Scheen AJ, "Cardiovascular effects of gliptins" 10 : 73-84, 2013

20 Ussher JR, "Cardiovascular biology of the incretin system" 33 : 187-215, 2012

21 Defronzo RA, "Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus" 58 : 773-795, 2009

22 Stratton IM, "Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study" 321 : 405-412, 2000

23 Iqbal N, "Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials" 13 : 33-, 2014

24 Goldfine AB, "Assessing the cardiovascular safety of diabetes therapies" 359 : 1092-1095, 2008

25 Radford MJ, "American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Failure Society of America. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Failure Society of America" 112 : 1888-1916, 2005